연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
1235. Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
Jung N, Won JK, Kim BH, Suh KS, Jang JJ, Kang GH.
J Korean Med Sci. 2012 Jun;27(6):594-604.
Link
1234. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
Park SY, Kwon HJ, Choi Y, Lee HE, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH.
Mod Pathol. 2012 Feb;25(2):185-96.
Link
1233. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.
Rhee YY, Kim MJ, Bae JM, Koh JM, Cho NY, Juhnn YS, Kim D, Kang GH.
Ann Surg Oncol. 2012 Oct;19(11):3441-8.
Link
1232. Bile-based detection of extrahepatic cholangiocarcinoma with quantitative DNA methylation markers and its high sensitivity.
Shin SH, Lee K, Kim BH, Cho NY, Jang JY, Kim YT, Kim D, Jang JJ, Kang GH.
J Mol Diagn. 2012 May-Jun;14(3):256-63.
Link
1231. ALU and LINE-1 hypomethylations in multistep gastric carcinogenesis and their prognostic implications.
Bae JM, Shin SH, Kwon HJ, Park SY, Kook MC, Kim YW, Cho NY, Kim N, Kim TY, Kim D, Kang GH.
Int J Cancer. 2012 Sep 15;131(6):1323-31.
Link
1230. Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment.
Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H, Park KD, Shin HY, Ahn HS.
J Hematol Oncol. 2012 Mar 30;5:14.
Link
1229. Early engraftment of G-CSF-primed allogeneic bone marrow transplantation in pediatric patients regardless of donor-recipient weight differences.
Kim H, Kang HJ, Lee JW, Park KD, Shin HY, Ahn HS.
Ann Hematol. 2012 May;91(5):751-8.
Link
1228. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Lee JW, Kang HJ, Lee SH, Yu KS, Kim NH, Yuk YJ, Jang MK, Han EJ, Kim H, Song SH, Park KD, Shin HY, Jang IJ, Ahn HS.
Biol Blood Marrow Transplant. 2012 Jun;18(6):944-50
Link
1227. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism.
Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y, Han BD, Choi JY, Kim CW, Lee JW, Park KD, Shin HY, Ahn HS.
PLoS One. 2012;7(9):e45558.
Link
1226. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
Kim H, Kim NH, Kang HJ, Lee JW, Kim MS, Park KD, Shin HY, Ahn HS.
Pediatr Transplant. 2012 Dec;16(8):910-2.
Link